Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.63 |
| ▸ | KLK1 | P06870 | 1/20 | 0.57 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.57 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.57 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.57 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 3/20 | 0.54 |
| ▸ | RXRB | P28702 | 2/20 | 0.54 |
| ▸ | RXRG | P48443 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16431953 | 0.88 | NR4A2 (0.57) | FFAR1NR4A2NR4A1NR4A3PTGER1 | |
| SCHEMBL977546 | 0.87 | FFAR1 (0.59) | FFAR1KLK1F2KMT2AHPGD | |
| SCHEMBL1600077 | 0.85 | MRGPRX4 (0.62) | NR4A2NR4A1NR4A3PTGER1MEN1 | |
| SCHEMBL29556736 | 0.85 | MRGPRX4 (0.62) | NR4A2NR4A1NR4A3PTGER1MEN1 | |
| SCHEMBL13846224 | 0.84 | FFAR1 (0.67) | FFAR1KLK1F2PTGER1HPGD | |
| Hydrochloric Acid SCHEMBL10857748 | 0.84 | MRGPRX4 (0.61) | NR4A2NR4A1NR4A3PTGER1MEN1 | |
| SCHEMBL1649243 | 0.83 | FOLH1 (0.68) | NR4A2NR4A1NR4A3PTGER1MEN1 | |
| SCHEMBL3965806 | 0.83 | EGFR (0.64) | NR4A2NR4A1NR4A3PTGER1MEN1 | |
| SCHEMBL27703695 | 0.81 | MRGPRX4 (0.57) | NR4A2NR4A1NR4A3PTGER1MEN1 | |
| SCHEMBL229472 | 0.81 | MRGPRX4 (0.69) | NR4A2NR4A1NR4A3PTGER1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | FFAR1 121/4885KLK1 3407/4885NR4A2 2102/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | FFAR1 113/4885KLK1 3165/4885NR4A2 2117/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | FFAR1 113/4885KLK1 3165/4885NR4A2 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.